儿童哮喘：基于指南的治疗、奥马珠单抗及其他潜在生物制剂
Pediatric asthma: guidelines-based care, omalizumab, and other potential biologic agents.
作者信息
Huffaker Michelle Fox, Phipatanakul Wanda
机构信息
Division of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
Division of Immunology, Boston Children's Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA.
出版信息
Immunol Allergy Clin North Am. 2015 Feb;35(1):129-44. doi: 10.1016/j.iac.2014.09.005. Epub 2014 Nov 21.
Abstract
Over the past several decades, the evidence supporting rational pediatric asthma management has grown considerably. As more is learned about the various phenotypes of asthma, the complexity of management will continue to grow. This article focuses on the evidence supporting the current guidelines-based pediatric asthma management and explores the future of asthma management with respect to phenotypic heterogeneity and biologics.
摘要
在过去几十年里，支持合理的儿童哮喘管理的证据大幅增加。随着对哮喘各种表型的了解越来越多，管理的复杂性将持续增加。本文重点关注支持当前基于指南的儿童哮喘管理的证据，并探讨哮喘管理在表型异质性和生物制剂方面的未来发展。
相似文献
1
Pediatric asthma: guidelines-based care, omalizumab, and other potential biologic agents.儿童哮喘：基于指南的治疗、奥马珠单抗及其他潜在生物制剂
Immunol Allergy Clin North Am. 2015 Feb;35(1):129-44. doi: 10.1016/j.iac.2014.09.005. Epub 2014 Nov 21.
2
What is the current role of biologics in the management of patients with severe refractory asthma?生物制剂在重度难治性哮喘患者管理中的当前作用是什么？
Ann Allergy Asthma Immunol. 2016 May;116(5):383-7. doi: 10.1016/j.anai.2016.03.021.
3
Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).奥马珠单抗作为附加疗法对重度过敏性哮喘患者哮喘相关生活质量的影响：一项巴西研究（QUALITX）。
J Asthma. 2012 Apr;49(3):288-93. doi: 10.3109/02770903.2012.660297. Epub 2012 Feb 23.
4
The potential of biologics for the treatment of asthma.生物制剂治疗哮喘的潜力。
Nat Rev Drug Discov. 2012 Dec;11(12):958-72. doi: 10.1038/nrd3792.
5
How do we interpret the data supporting the use of omalizumab for severe asthma?我们如何解读支持使用奥马珠单抗治疗重度哮喘的数据？
Ann Allergy Asthma Immunol. 2014 Oct;113(4):335-6. doi: 10.1016/j.anai.2014.07.008.
6
Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma.奥马珠单抗对未控制哮喘患者急诊就诊、住院和皮质类固醇使用的影响。
Ann Allergy Asthma Immunol. 2012 Jul;109(1):59-64. doi: 10.1016/j.anai.2012.04.015. Epub 2012 May 12.
7
Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma.奥马珠单抗：中重度过敏性哮喘疗效和安全性的最新进展。
Allergy Asthma Proc. 2012 Sep-Oct;33(5):377-85. doi: 10.2500/aap.2012.33.3599.
8
The relation of sTRAIL levels and quality of life in severe persistent allergic asthma patients using omalizumab.使用奥马珠单抗的重度持续性过敏性哮喘患者中可溶性肿瘤坏死因子相关凋亡诱导配体（sTRAIL）水平与生活质量的关系。
Med Sci Monit. 2012 Aug;18(8):LE9-10. doi: 10.12659/msm.883249.
9
Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.在严重变应性哮喘中进行长期奥马珠单抗治疗：东南地中海地区的“真实世界”经验。
Pulm Pharmacol Ther. 2012 Feb;25(1):77-82. doi: 10.1016/j.pupt.2011.11.004. Epub 2011 Dec 3.
10
Summaries for patients. Omalizumab therapy for patients with severe asthma.患者摘要。重度哮喘患者的奥马珠单抗治疗。
Ann Intern Med. 2011 May 3;154(9):I28. doi: 10.7326/0003-4819-154-9-201105030-00001.
引用本文的文献
1
Keeping Pace with Adolescent Asthma: A Practical Approach to Optimizing Care.紧跟青少年哮喘治疗进展：优化护理的实用方法
Pulm Ther. 2022 Mar;8(1):123-137. doi: 10.1007/s41030-021-00177-2. Epub 2021 Nov 6.
2
Taming Asthma in School-Aged Children: A Comprehensive Review.驯服学龄期儿童的哮喘：全面综述。
J Allergy Clin Immunol Pract. 2018 May-Jun;6(3):726-735. doi: 10.1016/j.jaip.2018.01.023.
本文引用的文献
1
Utility of the Asthma Predictive Index in predicting childhood asthma and identifying disease-modifying interventions.哮喘预测指数在预测儿童哮喘及识别疾病改善干预措施中的效用。
Ann Allergy Asthma Immunol. 2014 Mar;112(3):188-90. doi: 10.1016/j.anai.2013.12.001. Epub 2013 Dec 15.
2
Probiotic supplementation during pregnancy or infancy for the prevention of asthma and wheeze: systematic review and meta-analysis.孕期或婴儿期补充益生菌预防哮喘和喘息：系统评价和荟萃分析。
BMJ. 2013 Dec 4;347:f6471. doi: 10.1136/bmj.f6471.
3
Predictors of asthma control and lung function responsiveness to step 3 therapy in children with uncontrolled asthma.未控制哮喘儿童第 3 步治疗时哮喘控制和肺功能反应性的预测因素。
J Allergy Clin Immunol. 2014 Feb;133(2):350-6. doi: 10.1016/j.jaci.2013.07.039. Epub 2013 Sep 29.
4
Efficacy of sublingual specific immunotherapy on allergic asthma and rhinitis in children's real life.舌下特异性免疫治疗对儿童过敏性哮喘和鼻炎的疗效：真实世界研究。
Eur Rev Med Pharmacol Sci. 2013 Aug;17(16):2225-31.
5
IL-33 promotes airway remodeling in pediatric patients with severe steroid-resistant asthma.IL-33 促进儿童重症激素抵抗性哮喘患者的气道重塑。
J Allergy Clin Immunol. 2013 Sep;132(3):676-685.e13. doi: 10.1016/j.jaci.2013.04.012. Epub 2013 Jun 4.
6
Newer treatments in the management of pediatric asthma.小儿哮喘管理中的新疗法。
Paediatr Drugs. 2013 Aug;15(4):291-302. doi: 10.1007/s40272-013-0020-x.
7
Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU/mL: a retrospective study.奥马珠单抗治疗 IgE 水平高于 700 IU/mL 的哮喘患者的疗效：一项回顾性研究。
Ann Allergy Asthma Immunol. 2013 Jun;110(6):457-61. doi: 10.1016/j.anai.2013.04.011.
8
Dupilumab in persistent asthma with elevated eosinophil levels.度普利尤单抗治疗嗜酸性粒细胞水平升高的持续性哮喘。
N Engl J Med. 2013 Jun 27;368(26):2455-66. doi: 10.1056/NEJMoa1304048. Epub 2013 May 21.
9
Respiratory syncytial virus and recurrent wheeze in healthy preterm infants.呼吸道合胞病毒与健康早产儿反复喘息
N Engl J Med. 2013 May 9;368(19):1791-9. doi: 10.1056/NEJMoa1211917.
10
Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review.变应原特异性免疫疗法治疗儿童哮喘和鼻结膜炎：系统评价。
Pediatrics. 2013 Jun;131(6):1155-67. doi: 10.1542/peds.2013-0343. Epub 2013 May 6.
Zotero 插件